---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-005582"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:19:14.741560+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics closes $103.5M public offering of 69M shares at $1.50/share

## Summary
- Closed underwritten offering of 69,000,000 shares at $1.50, including 9M option shares.
- Gross proceeds of approximately $103.5M before underwriting discounts and expenses.
- Offering made under effective shelf registration statement (File No. 333-267777) filed Oct 2022.
- Lead book-running managers: Credit Suisse Securities and William Blair; Oppenheimer as passive book-runner.
- Company focuses on c-Kit antibody therapies for chronic spontaneous urticaria, MDS, and transplant conditioning.

## SEC filing metadata
- accession: 0001213900-23-005582
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023005582/0001213900-23-005582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023005582/ea172298-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-005582
- JSON: https://secwatch.observer/filing/0001213900-23-005582.json
- Plain text: https://secwatch.observer/filing/0001213900-23-005582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.